Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
M12.DE
Strong BuyFull HouseAPPROVEM1 Kliniken AG · Healthcare · Germany · $414M · Avg Vol: $97K/d
M1 Kliniken is executing a high-margin, asset-light 'beauty-as-a-service' model with demonstrable scale economics. Strong internal EPS revisions and clear margin expansion in the aesthetic division validate the thesis that consumers view these services as resilient despite macro uncertainty. The stock benefits from a focus on high-repeat, cash-pay procedures that are immune to typical healthcare reimbursement pressures.
COMPANY DESCRIPTION
M1 Kliniken AG is the leading provider of aesthetic medicine and plastic surgery services in Germany, operating a highly standardized network of specialized clinics. The company's competitive moat is driven by its high-volume, low-price strategy, supported by centralized procurement and distribution of medical products like dermal fillers and botulinum toxin. It operates as a dominant, vertically integrated player in the rapidly growing private-pay aesthetic healthcare market.
FINANCIAL SUMMARY (EUR)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 285.3M | 316.3M | 339.2M | 364.3M | 8.5% | 367.0M |
| EPS (EUR) | 0.24 | 0.54 | 0.85 | 1.19 | 70.5% | 1.20 |
| Shares | 18.3M | 19.1M | 18.8M | 18.8M | +2.5% | 18.8M |
| Debt | 13.7M | 10.8M | 10.4M | 7.1M | -19.5% | 10.3M |
| Equity | 95.5M | 113.3M | 106.1M | 119.9M | 7.9% | — |
| Op CF | 20.8M | 7.8M | 30.5M | 37.9M | 22.3% | 38.2M |
| Inv CF | -1.1M | -9.4M | -5.7M | -3.6M | — | — |
| Fin CF | -22.4M | -27.8M | -30.4M | -14.6M | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of M12.DE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| M12.DE | M1 Kliniken AG(you) | $414M | 99 | Strong Buy |
| ILM1.DE | Medios AG | $326M | 72 | Buy |
| MED.DE | MEDICLIN Aktiengesellschaft | $303M | 99 | Strong Buy |
| SBS.DE | Stratec SE | $317M | 87 | Strong Buy |
| LIK.DE | LIMES Schlosskliniken AG | $193M | 88 | Strong Buy |
| DRW8.DE | Drägerwerk AG & Co. KGaA | $1.8B | 99 | Strong Buy |
| RHK.DE | RHÖN-KLINIKUM Aktiengesellschaft | $1.1B | 87 | Strong Buy |
| EUZ.DE | Eckert & Ziegler SE | $960M | 77 | Buy |
| 1846.HK | EuroEyes International Eye Clinic Limited | $97M | 87 | Strong Buy |
| DMP.DE | Dermapharm Holding SE | $2.3B | 89 | Strong Buy |
Peer medians: ROE 5.7% · P/E 16.1x · Gross margin 45.7%